Comparison of serological assessments in the diagnosis of liver fibrosis in bile duct ligation mice

Abstract

Liver fibrosis assessment is essential to make a prognosis and to determine the appropriate anti-fibrosis treatment. Non-invasive serum markers are widely studied in patients to assess liver fibrosis due to the limitations of liver biopsy. When using animal models to study the mechanism and intervention of hepatic fibrosis, serum markers might be useful for the continuous assessment of liver fibrosis in individual animals, which could avoid the influence of biological differences between individuals. However, it is unclear whether serum markers can assess hepatic fibrosis in the animal model. In the present study, we evaluated and compared the ability of four serum markers to assess liver fibrosis in bile duct ligation mice. According to the stages of liver fibrosis assessed by pathological changes, mice in this study were divided into five groups (F0, F1, F2, F3, and F4). Subsequently, four serum markers, aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on the 4 factors (FIB-4), and Forns Index, were calculated for each group. Furthermore, the correlations between serum markers and pathological stages and the ability of serological markers to evaluate liver fibrosis were analyzed. AAR, APRI, FIB-4, and Forns Index could significantly distinguish F0-2 from F3-4 mice. APRI, FIB-4, and Forns Index could detect F0-3 from F4 mice. Among these four markers, FIB-4 was the best able to distinguish ≥F2 and ≥F3, with area under the curve values of 0.882 and 0.92, respectively. Forns Index was best for diagnosing F4 with area under the curve value of 0.879. These results demonstrated that serum markers could be used for assessing liver fibrosis in bile duct ligation mice, and therefore, these markers might lead to more accurate diagnostic and therapeutic studies through continuous monitoring in individual animals. Impact statement The assessment of liver fibrosis is essential for making a prognosis and determining the appropriate anti-fibrosis treatment. In studies focusing on the mechanism and treatment of liver fibrosis using animal models, it would be more accurate to continuously evaluate liver fibrosis in a single animal to avoid individual biological differences. Unfortunately, it is difficult to perform continuous assessment through liver biopsy in the most commonly used rodent models. It is unclear whether serum markers, which have been used in hepatic fibrosis patients, could be used in animal models. Our results demonstrate that serum markers could be used for assessing liver fibrosis in bile duct ligation mice. This study might contribute to more accurate diagnostic and therapeutic studies through continuous monitoring in individual animals.

Zinc-glutathione in Chinese Baijiu prevents alcohol-associated liver injury

“…Blood samples were obtained from the orbital varix before the mice were sacrificed. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using commercially available kits following the procedure described previously [ 16 ].…”

CD8 T cell hyperfunction and reduced tumour control in models of advanced liver fibrosis

“…At predetermined time points, animals were euthanized, and livers were immediately harvested, formalin-fixed and subsequently embedded in paraffin. To evaluate fibrosis severity, liver tissue sections were stained with Masson’s trichrome and scored by a skilled pathologist (Nour Histopathology Consultation Services, Ottawa, ON, Canada) following the METAVIR system (F0-1 minimal fibrosis to F4 advanced fibrosis/cirrhosis), which is used both clinically and in rodents 27 . Liver fibrosis regression was evaluated following the cessation of CCl 4 injections after ≈ 12 weeks, alongside continued control/CCl 4 treatments for a minimum of 4 weeks.…”